CHRS
Coherus Oncology, Inc.
CHRS
Coherus Oncology, Inc.
Coherus Oncology, Inc. (CHRS) Q2 2026 Earnings Call Transcript
Coherus Oncology enters a catalyst-rich period with multiple clinical readouts for tagmokitug and casdozokitug in H2'26 and H1'27. Prior anti-CCR8 clinical evidence supports potential efficacy in sele